Legend Biotech, Novartis partner to advance SCLC research

Divarasib monotherapy improves OS in previously-treated KRAS G12C-mutated lung cancer, phase III trial finds

Divarasib, a next-generation KRAS G12C inhibitor, lowered the risk of disease progression or death by 42% and the overall risk of death by 44% in people with previously treated KRAS G12C-mutated non-small cell lung cancer, according to the results from the phase III Krascendo 1 study. The therapy demonstrated the superior efficacy compared with current standard of care KRAS G12C inhibitors.

October 30, 2026

Vol.52 No.40

Podcast

As USPSTF falters, the idea that “screening is always good” is gaining traction

With the pope’s lung cancer diagnosis jumpstarting conversations about lung cancer screening and the constant buzz surrounding multi-cancer detection tests, evidence-based evaluation of screening tests is more important than ever.

October 21, 2026

News Analysis

The lung cancer diagnosis of Pope Leo—believed to be a never-smoker—sparks conversations around screening
“Even when the patient is the pope, advances in cancer treatment don’t arrive by divine intervention.”

Pope Leo XIV has been diagnosed with lung adenocarcinoma. According to missives from the Holy See, the pope underwent surgery to remove the lower lobe of his right lung Oct. 13.

Cigarette smoke may prime lung stem cells for different types of lung cancer, Hopkins study finds

Chronic exposure to cigarette smoke may reprogram different populations of lung stem cells, which maintain and repair lung tissue, in ways that make them vulnerable to specific cancer-causing gene alterations and ultimately helps determine the type of lung cancer that develops.

October 09, 2026

Vol.52 No.37

Clinical Roundup

Lung cancers can use two different mechanisms to evade KRAS-inhibiting drug, MIT researchers find

About 25% of lung adenocarcinomas have mutations of the gene KRAS, which drives uncontrolled cell growth. In recent years, FDA has approved two KRAS inhibitors to treat patients with specific KRAS mutations. While these drugs can work well initially, tumors almost always develop resistance to them.

October 02, 2026

Vol.52 No.36

Perspective

When did stage 3B lung cancer become “early stage”?

My recent column about Merck’s television commercial for perioperative Keytruda left me with a question I could not shake.

September 25, 2026

Vol.52 No.35

By Raja M. Flores

Legend Biotech, Novartis partner to advance SCLC research

YOU MAY BE INTERESTED IN

Divarasib monotherapy improves OS in previously-treated KRAS G12C-mutated lung cancer, phase III trial finds

As USPSTF falters, the idea that “screening is always good” is gaining traction

The lung cancer diagnosis of Pope Leo—believed to be a never-smoker—sparks conversations around screening
“Even when the patient is the pope, advances in cancer treatment don’t arrive by divine intervention.”

Cigarette smoke may prime lung stem cells for different types of lung cancer, Hopkins study finds

Lung cancers can use two different mechanisms to evade KRAS-inhibiting drug, MIT researchers find

When did stage 3B lung cancer become “early stage”?

Renew today!

Subscriber content

Never miss an issue!

Login

Legend Biotech, Novartis partner to advance SCLC research

YOU MAY BE INTERESTED IN

Divarasib monotherapy improves OS in previously-treated KRAS G12C-mutated lung cancer, phase III trial finds

As USPSTF falters, the idea that “screening is always good” is gaining traction

The lung cancer diagnosis of Pope Leo—believed to be a never-smoker—sparks conversations around screening“Even when the patient is the pope, advances in cancer treatment don’t arrive by divine intervention.”

Cigarette smoke may prime lung stem cells for different types of lung cancer, Hopkins study finds

Lung cancers can use two different mechanisms to evade KRAS-inhibiting drug, MIT researchers find

When did stage 3B lung cancer become “early stage”?

Never miss an issue!

Login

The lung cancer diagnosis of Pope Leo—believed to be a never-smoker—sparks conversations around screening
“Even when the patient is the pope, advances in cancer treatment don’t arrive by divine intervention.”